Literature DB >> 10913477

Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy.

S Sharma1, P Elliott, G Whyte, S Jones, N Mahon, B Whipp, W J McKenna.   

Abstract

The utility of metabolic gas exchange measurements in evaluating the severity and determinants of exercise limitation was studied during upright symptom-limited cardiopulmonary exercise in 135 consecutive patients with hypertrophic cardiomyopathy (HC) and 50 healthy age- and gender-matched volunteers. Peak oxygen consumption (VO(2)) was less than predicted (age, gender, and size) in 99% patients. Peak VO(2) was significantly associated with New York Heart Association functional class; however, there was considerable overlap of peak VO(2) between classes I and III (70 +/- 15%, 56 +/- 15%, 35 +/- 11%, respectively). Patients with abnormal blood pressure responses and patients with chronotropic incompetence during exercise had lower percent-predicted peak VO(2) than patients with normal blood pressure and heart rate responses during exercise (p = 0.0001 and p <0.001, respectively). Percent-predicted peak VO(2) was similar in patients with and without resting left ventricular outflow obstruction. Of those patients with resting gradients, however, there was a strong inverse correlation between the magnitude of the gradient and peak VO(2) (r = 0.5; p <0.001). In conclusion, peak VO(2) is significantly related to New York Heart Association functional class in this group of patients with HC, but peak VO(2) is a superior measure of cardiovascular performance in individual patients. Our peak VO(2) data indicate that mechanical obstruction has an adverse pathophysiologic effect on functional capacity and provide the rationale to support treatments aimed at gradient reduction. Low peak VO(2) characteristics including those with normal or near-normal left ventricular wall thickness suggests that measurement of peak VO(2) may aid in the differential diagnosis between HC and athlete's heart.

Entities:  

Mesh:

Year:  2000        PMID: 10913477     DOI: 10.1016/s0002-9149(00)00854-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  34 in total

1.  Exercise in hypertrophic cardiomyopathy.

Authors:  Sharlene M Day
Journal:  J Cardiovasc Transl Res       Date:  2009-10-14       Impact factor: 4.132

2.  Similarities in the profile of cardiopulmonary exercise testing between patients with hypertrophic cardiomyopathy and strength athletes.

Authors:  A Anastasakis; C Kotsiopoulou; A Rigopoulos; A Theopistou; N Protonotarios; D Panagiotakos; N Mammalis; C Stefanadis
Journal:  Heart       Date:  2005-11       Impact factor: 5.994

3.  Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.

Authors:  Georgios K Efthimiadis; Areti Hitoglou-Makedou; Georgios Giannakoulas; Anastasia Mitakidou; Theodoros Karamitsos; Haralambos Karvounis; Sotirios Mochlas; Ioannis Styliadis; Haris Stefanidis; Georgios Parcharidis; Georgios Louridas
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

4.  Effects of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: relationship to cardiac output reserve.

Authors:  Gunnar Plehn; Julia Vormbrock; Axel Meissner; Hans-Joachim Trappe
Journal:  J Nucl Cardiol       Date:  2009-01-22       Impact factor: 5.952

5.  Early diastolic function during exertion influences exercise intolerance in patients with hypertrophic cardiomyopathy.

Authors:  Kei Mizukoshi; Kengo Suzuki; Kihei Yoneyama; Ryo Kamijima; Seisyou Kou; Manabu Takai; Masaki Izumo; Akio Hayashi; Eiji Ohtaki; Yoshihiro J Akashi; Naohiko Osada; Kazuto Omiya; Tomoo Harada; Sachihiko Nobuoka; Fumihiko Miyake
Journal:  J Echocardiogr       Date:  2012-10-19

6.  The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019.

Authors:  Nabil Ghorayeb; Ricardo Stein; Daniel Jogaib Daher; Anderson Donelli da Silveira; Luiz Eduardo Fonteles Ritt; Daniel Fernando Pellegrino Dos Santos; Ana Paula Rennó Sierra; Artur Haddad Herdy; Claúdio Gil Soares de Araújo; Cléa Simone Sabino de Souza Colombo; Daniel Arkader Kopiler; Filipe Ferrari Ribeiro de Lacerda; José Kawazoe Lazzoli; Luciana Diniz Nagem Janot de Matos; Marcelo Bichels Leitão; Ricardo Contesini Francisco; Rodrigo Otávio Bougleux Alô; Sérgio Timerman; Tales de Carvalho; Thiago Ghorayeb Garcia
Journal:  Arq Bras Cardiol       Date:  2019-03       Impact factor: 2.000

7.  Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy.

Authors:  Tomas Konecny; Jeffrey B Geske; Ondrej Ludka; Marek Orban; Peter A Brady; Muaz M Abudiab; Felipe N Albuquerque; Alexander Placek; Tomas Kara; Karine R Sahakyan; Bernard J Gersh; A Jamil Tajik; Thomas G Allison; Steve R Ommen; Virend K Somers
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

8.  Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study.

Authors:  Damiano Magrì; Piergiuseppe Agostoni; Filippo Maria Cauti; Beatrice Musumeci; Gabriele Egidy Assenza; Carlo Nicola De Cecco; Giuseppe Muscogiuri; Antonello Maruotti; Agnese Ricotta; Erika Pagannone; Laura Marino; Daria Santini; Giulia Proietti; Andrea Serdoz; Francesco Paneni; Massimo Volpe; Camillo Autore
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

Review 9.  Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease.

Authors:  Ardan M Saguner; Corinna Brunckhorst; Firat Duru
Journal:  World J Cardiol       Date:  2014-04-26

10.  Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure.

Authors:  Ercan Varol; Mehmet Ozaydin; Ahmet Altinbas; Suleyman M Aslan; Abdullah Dogan; Ozkan Dede
Journal:  Heart Vessels       Date:  2007-01-26       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.